Kura Oncology (KURA) Accounts Payables (2010 - 2026)

Kura Oncology (KURA) has 17 years of Accounts Payables data on file, last reported at $7.0 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 84.38% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 84.38% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, up 241.52% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.0 million, up from $5.0 million in the prior quarter.
• Over the last five years, Accounts Payables for KURA reached as high as $66.8 million in Q3 2025 and fell as low as $1.3 million in Q1 2022.
• Historically, Accounts Payables has averaged $24.3 million across 5 years, with a median of $21.7 million in 2022.
• Across the five-year window, Accounts Payables surged 1164.1% in 2023 and slumped 95.65% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $21.7 million in 2022, then soared by 55.28% to $33.8 million in 2023, then slumped by 95.65% to $1.5 million in 2024, then soared by 241.52% to $5.0 million in 2025, then jumped by 40.38% to $7.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $7.0 million in Q1 2026, $5.0 million in Q4 2025, and $66.8 million in Q3 2025.